InterAx Biotech celebrated Christmas with a seed financing round
06.01.2017
InterAx Biotech, a spin-off of ETH Zurich and Paul Scherrer Institute, closed a seed financing round with a team of Boston based biotech investors over Christmas.
 InterAx Biotech won the final of Venture Kick in 2016
|
 |
InterAx Biotech, a 2016 Venture Kick winner and a venture leader in Life Sciences 2016, is developing different assets for the discovery of functionally selective drugs with improved efficacy and reduced side effects for the largest class of human receptors: the G-Protein coupled Receptors (GPCRs). The uniqueness of InterAx lies in the combination of protein-based IP-protected biosensors and mathematical modelling of signaling pathways.